drugset / Trial / NCT03879057
Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, phase I study evaluating safety, tolerability, pharmacokinetics and efficacy of Surufatinib combined with the humanized anti-PD-1 antibody JS001 in patients with solid tumors.
Timeline
- Start
- 2018-12-21
- Primary completion
- 2020-12-20
- Completion
- 2021-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 200 mg | — |
| Subject | Surufatinib | Small molecule | 250 mg | — |
| Subject | Surufatinib | Small molecule | 300 mg | — |
| Background | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |